SEARCH

SEARCH BY CITATION

References

  • Alexander SP, Mathie A, Peters JA (2008). Guide to receptors and channels (GRAC), 3rd edition. Br J Pharmacol 153 (Suppl.2): S1–S209.
  • Andrade-Gordon P, Maryanoff BE, Derian CK, Zhang HC, Addo MF, Darrow AL et al. (1999). Design, synthesis, and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptor. Proc Natl Acad Sci USA 96: 1225712262.
  • Azzi M, Charest PG, Angers S, Rousseau G, Kohout T, Bouvier M et al. (2003). Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc Natl Acad Sci USA 100: 1140611411.
  • Baker JG, Hill SJ (2007). Multiple GPCR conformations and signalling pathways: implications for antagonist affinity estimates. Trends Pharmacol Sci 28: 374381.
  • Cenac N, Coelho AM, Nguyen C, Compton S, Andrade-Gordon P, MacNaughton WK et al. (2002). Induction of intestinal inflammation in mouse by activation of proteinase-activated receptor-2. Am J Pathol 161: 19031915.
  • Cenac N, Garcia-Villar R, Ferrier L, Larauche M, Vergnolle N, Bunnett NW et al. (2003). Proteinase-activated receptor-2-induced colonic inflammation in mice: possible involvement of afferent neurons, nitric oxide, and paracellular permeability. J Immunol 170: 42964300.
  • Chackalamannil S (2006). Thrombin receptor (protease activated receptor-1) antagonists as potent antithrombotic agents with strong antiplatelet effects. J Med Chem 49: 53895403.
  • Charest PG, Oligny-Longpre G, Bonin H, Azzi M, Bouvier M (2007). The V2 vasopressin receptor stimulates ERK1/2 activity independently of heterotrimeric G protein signalling. Cell Signal 19: 3241.
  • Damiano BP, Derian CK, Maryanoff BE, Zhang HC, Gordon PA (2003). RWJ-58259: a selective antagonist of protease activated receptor-1. Cardiovasc Drug Rev 21: 313326.
  • Darieva Z, Lasunskaia EB, Campos MN, Kipnis TL, Da Silva WD (2004). Activation of phosphatidylinositol 3-kinase and c-Jun-N-terminal kinase cascades enhances NF-kappaB-dependent gene transcription in BCG-stimulated macrophages through promotion of p65/p300 binding. J Leukoc Biol 75: 689697.
  • Darmoul D, Gratio V, Devaud H, Laburthe M (2004). Protease-activated receptor 2 in colon cancer: trypsin-induced MAPK phosphorylation and cell proliferation are mediated by epidermal growth factor receptor transactivation. J Biol Chem 279: 2092720934.
  • Ferrell WR, Lockhart JC, Kelso EB, Dunning L, Plevin R, Meek SE et al. (2003). Essential role for proteinase-activated receptor-2 in arthritis. J Clin Invest 111: 3541.
  • Goon Goh F, Sloss CM, Cunningham MR, Nilsson M, Cadalbert L, Plevin R (2008). G-protein-dependent and -independent pathways regulate proteinase-activated receptor-2 mediated p65 NFkappaB serine 536 phosphorylation in human keratinocytes. Cell Signal 20: 12671274.
  • Granneman JG (2001). The putative beta4-adrenergic receptor is a novel state of the beta1-adrenergic receptor. Am J Physiol Endocrinol Metab 280: E199–E202.
  • Kanke T, Macfarlane SR, Seatter MJ, Davenport E, Paul A, McKenzie RC et al. (2001). Proteinase-activated receptor-2-mediated activation of stress-activated protein kinases and inhibitory kappa B kinases in NCTC 2544 keratinocytes. J Biol Chem 276: 3165731666.
  • Kanke T, Takizawa T, Kabeya M, Kawabata A (2005). Physiology and pathophysiology of proteinase-activated receptors (PARs): PAR-2 as a potential therapeutic target. J Pharmacol Sci 97: 3842.
  • Kanke T, Kabeya M, Kubo S, Kondo S, Yasuoka K, Tagashira J et al. (2009). Novel antagonists for proteinase-activated receptor 2: inhibition of cellular and vascular responses in vitro and in vivo. Br J Pharmacol 158: 361–371.
  • Kawabata A, Kanke T, Yonezawa D, Ishiki T, Saka M, Kabeya M et al. (2004). Potent and metabolically stable agonists for protease-activated receptor-2: evaluation of activity in multiple assay systems in vitro and in vivo. J Pharmacol Exp Ther 309: 10981107.
  • Kawagoe J, Takizawa T, Matsumoto J, Tamiya M, Meek SE, Smith AJ et al. (2002). Effect of protease-activated receptor-2 deficiency on allergic dermatitis in the mouse ear. Jpn J Pharmacol 88: 7784.
  • Kelso EB, Lockhart JC, Hembrough T, Dunning L, Plevin R, Hollenberg MD et al. (2006). Therapeutic promise of proteinase-activated receptor-2 antagonism in joint inflammation. J Pharmacol Exp Ther 316: 10171024.
  • Kim SJ, Hwang SG, Shin DY, Kang SS, Chun JS (2002). p38 kinase regulates nitric oxide-induced apoptosis of articular chondrocytes by accumulating p53 via NFkappa B-dependent transcription and stabilization by serine 15 phosphorylation. J Biol Chem 277: 3350133508.
  • Korus M, Mahon GM, Cheng L, Whitehead IP (2002). p38 MAPK-mediated activation of NF-kappaB by the RhoGEF domain of Bcr. Oncogene 21: 46014612.
  • Kumar P, Lau CS, Mathur M, Wang P, DeFea KA (2007). Differential effects of beta-arrestins on the internalization, desensitization and ERK1/2 activation downstream of protease activated receptor-2. Am J Physiol Cell Physiol 293: C346–C357.
  • Macfarlane SR, Seatter MJ, Kanke T, Hunter GD, Plevin R (2001). Proteinase-activated receptors. Pharmacol Rev 53: 245282.
  • Macfarlane SR, Sloss CM, Cameron P, Kanke T, McKenzie RC, Plevin R (2005). The role of intracellular Ca2+ in the regulation of proteinase-activated receptor-2 mediated nuclear factor kappa B signalling in keratinocytes. Br J Pharmacol 145: 535544.
  • McIntosh KA, Plevin R, Ferrell WR, Lockhart JC (2007). The therapeutic potential of proteinase-activated receptors in arthritis. Curr Opin Pharmacol 7: 334338.
  • Maryanoff BE, Zhang HC, Andrade-Gordon P, Derian CK (2003). Discovery of potent peptide-mimetic antagonists for the human thrombin receptor, protease-activated receptor-1 (PAR-1). Curr Med Chem Cardiovasc Hematol Agents 1: 1336.
  • Molenaar P (2003). The ‘state’ of beta-adrenoceptors. Br J Pharmacol 140: 12.
  • Nystedt S, Emilsson K, Wahlestedt C, Sundelin J (1994). Molecular cloning of a potential proteinase activated receptor. Proc Natl Acad Sci USA 91: 92089212.
  • Ossovskaya VS, Bunnett NW (2004). Protease-activated receptors: contribution to physiology and disease. Physiol Rev 84: 579621.
  • Paul A, Torrie LJ, McLaren GJ, Kennedy C, Gould GW, Plevin R (2000). P2Y receptor-mediated inhibition of tumor necrosis factor alpha -stimulated stress-activated protein kinase activity in EAhy926 endothelial cells. J Biol Chem 275: 1324313249.
  • Plevin R, Kellock NA, Wakelam MJ, Wadsworth R (1994). Regulation by hypoxia of endothelin-1-stimulated phospholipase D activity in sheep pulmonary artery cultured smooth muscle cells. Br J Pharmacol 112: 311315.
  • Ramachandran R, Sadofsky LR, Xiao Y, Botham A, Cowen M, Morice AH et al. (2007). Inflammatory mediators modulate thrombin and cathepsin-G signaling in human bronchial fibroblasts by inducing expression of proteinase-activated receptor-4. Am J Physiol Lung Cell Mol Physiol 292: L788–L798.
  • Ritchie E, Saka M, Mackenzie C, Drummond R, Wheeler-Jones C, Kanke T et al. (2007). Cytokine upregulation of proteinase-activated-receptors 2 and 4 expression mediated by p38 MAP kinase and inhibitory kappa B kinase beta in human endothelial cells. Br J Pharmacol 150: 10441054.
  • Schreiber E, Matthias P, Muller MM, Schaffner W (1989). Rapid detection of octamer binding proteins with ‘mini-extracts’ prepared from a small number of cells. Nucleic Acids Res 17: 6419.
  • Seeliger S, Derian CK, Vergnolle N, Bunnett NW, Nawroth R, Schmelz M et al. (2003). Proinflammatory role of proteinase-activated receptor-2 in humans and mice during cutaneous inflammation in vivo. FASEB J 17: 18711885.
  • Steinhoff M, Vergnolle N, Young SH, Tognetto M, Amadesi S, Ennes HS et al. (2000). Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. Nat Med 6: 151158.
  • Takasaki J, Saito T, Taniguchi M, Kawasaki T, Moritani Y, Hayashi K et al. (2004). A novel Gαq/11-selective inhibitor. J Biol Chem 279: 4743847445.
  • Wang P, DeFea KA (2006). Protease-activated receptor-2 simultaneously directs beta-arrestin-1-dependent inhibition and Galphaq-dependent activation of phosphatidylinositol 3-kinase. Biochemistry 45: 93749385.
  • Wei H, Ahn S, Shenoy SK, Karnik SS, Hunyady L, Luttrell LM et al. (2003). Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc Natl Acad Sci USA 100: 1078210787.
  • Yoshida N, Katada K, Handa O, Takagi T, Kokura S, Naito Y et al. (2007). Interleukin-8 production via protease-activated receptor 2 in human esophageal epithelial cells. Int J Mol Med 19: 335340.